Lineage Cell Therapeutics Inc. (LCTX)
Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago.
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript
Lineage Cell (LCTX) Reports Break-Even Earnings for Q4
Lineage Cell (LCTX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.01 per share a year ago.
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2025 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. ( LCTX ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Ioana Hone - Director of Investor Relations Brian Culley - CEO, President & Director Jill Howe - CFO & Principal Financial and Accounting Officer Conference Call Participants William Wood - B. Riley Securities, Inc., Research Division Joseph Pantginis - H.C.
Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates
Lineage Cell (LCTX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago.
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2025 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Brian M. Culley - CEO, President & Director Ioana C.
Lineage Cell (LCTX) Reports Q2 Loss, Beats Revenue Estimates
Lineage Cell (LCTX) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.03 per share a year ago.
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Lineage Cell (LCTX) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago.
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2025 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q1 2025 - Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Conference Call Participants William Wood - B. Riley Securities Jack Allen - Baird Michael Okunewitch - Maxim Group Albert Lowe - Craig Hallum Capital Group Operator Welcome to the Lineage Cell Therapeutics First Quarter 2025 Conference Call.
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2024 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q4 2024 Earnings Conference Call March 10, 2025 4:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Conference Call Participants Jack Allen - Baird Joseph Pantginis - H.C. Wainwright Michael Okunewitch - Maxim Group Mayank Mamtani - Riley Securities Albert Lowe - Craig-Hallum Sean McCutcheon - Raymond James Operator Thank you for standing by.
